Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.

摘要: TNF-alpha is a crucial cytokine in the establishment and maintenance of inflammation multiple autoimmune non-autoimmune disorders. A number large placebo-controlled trials have shown that infliximab, chimeric monoclonal antibody against TNF-alpha, effective well-tolerated patients with Crohn's disease rheumatoid arthritis (RA) has become widely used treatment for these diseases. More recent controlled also effectiveness blockers psoriasis, psoriatic arthritis, ankylosing spondylitis. The results clinical trials, open-label studies, case studies indicate TNF inhibitors (alone or combination other protocols) look very promising variety conditions, including uveitis, sarcoidosis, Sjogren's syndrome (SS), Behcet's syndrome, vasculitis, graft versus host disease. There rationale using blockade even systemic lupus erythematosus, prototype autoantibody-mediated disease, pilot study seems to confirm this potential approach. neutralisation might therefore play role many disorders than RA. We here review current prospective roles infliximab diseases conditions do not currently FDA EMEA approval.